Consumption pattern of enoxaparin in a non-teaching hospital (a cross-sectional prospective study)
,
Abstract
Background: Drug use evaluation studies are conducted to assess the pattern of prescribing and administration of a drug. Deep vein thrombosis is one of the most important clinical issues around the world. This study examined the pattern of enoxaparin consumption, one of the most widely used anticoagulant, for prevention and treatment of thrombosis in a non-teaching hospital. Methods: In this cross-sectional prospective study, 117 patients receiving enoxaparin in different wards of Imam Sajjad Hospital in Ramsar, Iran were studied. Data on how to prescribe and use of enoxaparin were recorded in a questionnaire designed according to UpToDate recommendations. Demographic variables, prophylaxis and therapeutic indications, prophylaxis and treatment doses, interval and monitoring information were evaluated. Finally, the results were compared with UpToDate suggestions. Results: The mean age of patients was 68.9 years and 52.1% of them were men. Enoxaparin was prescribed for 35.9% of patients as prophylaxis and 64.1% of patients received this drug for the treatment. Overall, prophylactic doses were inappropriately administered in 41.5% of patients. Improper therapeutic doses were also prescribed for 52% of subjects. Conclusion: The results of this study showed that the dosage and interval of enoxaparin administration were significantly inappropriate. It seems, the prescribers must consider more adherence to enoxaparin guidelines and reliable sources for more rational practices.
1. Organization WH. Introduction to drug utilization research. 2003.
2. Organization WH. WHO Policy Perspectives on Medicines-Promoting rational use of medicines: core components. World Health Organization, Geneva, Switzerland. 2002.
3. Harter K LM, Henderson SO. Anticoagulation drug therapy: a review. West J Emerg Med. 2015;16(1):11-7.
4. Garcia DA BT, Weitz JI, Samama MM. Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. . Chest 2012;41(2 Suppl):245-435.
5. LB. M. Heparin-induced thrombocytopenia: clinical manifestations and management strategies. The American Journal of Medicine. 2005;118(8 supp.):21-30.
6. Hirsh J BK, Donati MB, Gould M, Samama MM, Weitz JI. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 supp):141s-59s.
7. Hassani A GK, Hajhoseintalasaz A, Mohebi N, Hassani E. . ENOXAPARIN UTILIZATION EVALUATION IN A CARDIOVASCULAR TEACHING HOSPITAL. Studies in Medical Sciences. 2014;2014(25):3.
8. Khalili H D-KS, Talasaz AH, Najmedin F, Hosseinpoor R. Anticoagulant utilization evaluation in a teaching hospital: a prospective study. J Pharm Pract. 2010;23(6):579-84.
9. Fahimi F, Baniasadi, S., Behzadnia, N., Varahram, F., Ghazi Tabatabaie, L. Enoxaparin Utilization Evaluation: An Observational Prospective Study in Medical Inpatients. Iranian Journal of Pharmaceutical Research,. 2010;7(1):77-82.
10. Emadian A AM, Jafarirad A, Rafati M, Yahyazade Hajikolaee S, Naderi F, et al . Administration of Enoxaparin in Hospitalized Burn Patients in North of Iran. J Mazandaran Univ Med Sci. 2019;29(177):69-80.
11. Chung YL NK, Lai KW. Drug Utilization Evaluation (DUE) on Enoxaparin in Venous Thromboembolism (VTE) Prophylaxis for Hip and Knee Replacement Surgery. J Mol Biomark Diagn. 2017;8(3):329.
12. Nekoonam B, Azadeh Eshraghi, Mohammadreza Hajiesmaeili and Zahra Sahraei. Deep Vein Thrombosis Prophylaxis Evaluation in Intensive Care Unit. Arch Crit Care Med. 2016;1(4):e8497.
13. Eslami G AS, Emami S. Clinical Evaluation of Enoxaparin Prescription in Mazandaran Heart Center. J Mazandaran Univ Med Sci. 2020;30(186):156-62.
14. Zeitoun AA, Nassif, J.G. & Zeineddine, M.M. The appropriateness of enoxaparin use in Lebanese hospitals: a quality evaluation study. . Int J Clin Pharm. 2011;33(934-941).
15. Lim W DF, Eikelboom JW, Crowther MA. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med. 2006;144(9):673-84.
16. Witt Daniel M. CNP, Skov Jane,Crowther Mark. . CLINICAL PRACTICE GUIDELINES: VENOUS THROMBOEMBOLISM (VTE), A POCKET GUIDE FOR THE CLINICIAN. American Society of Hematology. 2019.
17. LLC s-aUS. Lovenox. 2022.
2. Organization WH. WHO Policy Perspectives on Medicines-Promoting rational use of medicines: core components. World Health Organization, Geneva, Switzerland. 2002.
3. Harter K LM, Henderson SO. Anticoagulation drug therapy: a review. West J Emerg Med. 2015;16(1):11-7.
4. Garcia DA BT, Weitz JI, Samama MM. Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. . Chest 2012;41(2 Suppl):245-435.
5. LB. M. Heparin-induced thrombocytopenia: clinical manifestations and management strategies. The American Journal of Medicine. 2005;118(8 supp.):21-30.
6. Hirsh J BK, Donati MB, Gould M, Samama MM, Weitz JI. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 supp):141s-59s.
7. Hassani A GK, Hajhoseintalasaz A, Mohebi N, Hassani E. . ENOXAPARIN UTILIZATION EVALUATION IN A CARDIOVASCULAR TEACHING HOSPITAL. Studies in Medical Sciences. 2014;2014(25):3.
8. Khalili H D-KS, Talasaz AH, Najmedin F, Hosseinpoor R. Anticoagulant utilization evaluation in a teaching hospital: a prospective study. J Pharm Pract. 2010;23(6):579-84.
9. Fahimi F, Baniasadi, S., Behzadnia, N., Varahram, F., Ghazi Tabatabaie, L. Enoxaparin Utilization Evaluation: An Observational Prospective Study in Medical Inpatients. Iranian Journal of Pharmaceutical Research,. 2010;7(1):77-82.
10. Emadian A AM, Jafarirad A, Rafati M, Yahyazade Hajikolaee S, Naderi F, et al . Administration of Enoxaparin in Hospitalized Burn Patients in North of Iran. J Mazandaran Univ Med Sci. 2019;29(177):69-80.
11. Chung YL NK, Lai KW. Drug Utilization Evaluation (DUE) on Enoxaparin in Venous Thromboembolism (VTE) Prophylaxis for Hip and Knee Replacement Surgery. J Mol Biomark Diagn. 2017;8(3):329.
12. Nekoonam B, Azadeh Eshraghi, Mohammadreza Hajiesmaeili and Zahra Sahraei. Deep Vein Thrombosis Prophylaxis Evaluation in Intensive Care Unit. Arch Crit Care Med. 2016;1(4):e8497.
13. Eslami G AS, Emami S. Clinical Evaluation of Enoxaparin Prescription in Mazandaran Heart Center. J Mazandaran Univ Med Sci. 2020;30(186):156-62.
14. Zeitoun AA, Nassif, J.G. & Zeineddine, M.M. The appropriateness of enoxaparin use in Lebanese hospitals: a quality evaluation study. . Int J Clin Pharm. 2011;33(934-941).
15. Lim W DF, Eikelboom JW, Crowther MA. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med. 2006;144(9):673-84.
16. Witt Daniel M. CNP, Skov Jane,Crowther Mark. . CLINICAL PRACTICE GUIDELINES: VENOUS THROMBOEMBOLISM (VTE), A POCKET GUIDE FOR THE CLINICIAN. American Society of Hematology. 2019.
17. LLC s-aUS. Lovenox. 2022.
| Files | ||
| Issue | Vol 8 No 4 (2022) | |
| Section | Original Article(s) | |
| Keywords | ||
| Low molecular weight heparin, DUE, Dose, Interval | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
Rafati M, Ala S, Heydari M, Lashto-Aghaee B. Consumption pattern of enoxaparin in a non-teaching hospital (a cross-sectional prospective study). JPPM. 2022;8(4):17-21.
